934192-22-0

Usage

Chemical class

Quinolone derivatives A class of chemical compounds that have a quinoline ring fused to a second ring, which can be a six-membered or a five-membered ring.

Common use

Medicinal chemistry It is widely used in the synthesis of various pharmaceuticals, including anti-cancer agents and antibiotics.

Structural features

Benzyl group attached to the carbonyl group at the first position The presence of a benzyl group (C6H5-CH2-) attached to the carbonyl group (C=O) at the first position of the molecule.

Structural features

2,3-dihydro-4-quinolone ring system The molecule contains a 2,3-dihydro-4-quinolone ring system, which is a partially saturated quinolone ring with two hydrogen atoms added to the second and third positions.

Potential application

Treatment of various diseases It has been studied for its potential application in the treatment of various diseases due to its promising pharmacological activities.

Pharmacological activities

Anticancer and antibiotic properties The compound has shown promising pharmacological activities, particularly in the areas of cancer treatment and antibiotic development.

Importance in drug design

Valuable tool The compound's structure and properties make it a valuable tool for drug design and development, as it can be modified and optimized to create new therapeutic agents.

Field of interest

Medicinal chemistry 1-benzyloxycarbonyl-2,3-dihydro-4-quinolone continues to be of interest in the field of medicinal chemistry due to its potential applications and the ongoing research in this area.

Upstream product

• 4295-36-7 2,3-dihydroquinolin-4(1H)-one 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 1146211-13-3 C₂₀H₁₉NO₃ 
• 934192-24-2 (S)-1-benzyloxycarbonyl-4-tert-butyldimethylsilyloxy-1,2,3,4-tetrahydroquinoline 

Relevant academic research and scientific papers

Intramolecular Büchner reaction and oxidative aromatization with SeO2 or O2

Intramolecular Büchner reaction of 1-diazo-5-phenylpentan-2-ones followed by oxidation with SeO2 or O2 in the presence of silica gel regioselectively gave 8-formyl-1-tetralones or one-carbon-lacking 1-tetralones, respectively.

COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY

The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, R27, R28, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions

SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY

The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising t

DERMATITIS REMEDIES

The present invention is to provide a topical dermatitis treating agent which comprises a pyridine compound represented by the following formula [I]: wherein R1 and R2 each represent a lower alkoxy group, =X- represents a group repre

OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PRODUCING SAME

Disclosed is a method for producing an optically active cyclic alcohol compound represented by the general formula [I] below, wherein a cyclic ketone compound represented by the general formula [II] below is asymmetrically reduced in the presence of (A) an optically active oxazaborolidine compound and a boron hydride compound, or alternatively in the presence of (B) an asymmetric transition metal complex obtained from a transition metal compound and an asymmetric ligand, and a hydrogen donor. Also disclosed is such an optically active cyclic alcohol compound. [I] (In the formula, the symbol is as defined below.) [II] (In the formula, R represents a hydrogen atom or a protective group of an amino group.)